Spots Global Cancer Trial Database for Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
Official Title: Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Study ID: NCT03464201
Conditions
Interventions
Study Description
Brief Summary: The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Hospital de Mar, Barcelona, , Spain
Hospital Reina Sofia, Córdoba, , Spain
Hospital Madrid Sanchinarro (CIOCC), Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
Hospital Son Llatzer, Palma De Mallorca, , Spain
Hospital de Navarra, Pamplona, , Spain
Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, , Spain
Hospital La Fe, Valencia, , Spain
Contact Details
Name: Garcia-Donas, MD
Affiliation: CIOCC (Hospital Universitario HM Sanchinarro)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
